42
Participants
Start Date
January 22, 2019
Primary Completion Date
July 12, 2022
Study Completion Date
July 12, 2022
ABP 959
intravenous infusion
Eculizumab
intravenous infusion
Saint James's Hospital, Dublin
Univerzitetni klinični center Ljubljana, Ljubljana
Azienda Ospedaliera S. Croce e Carle Cuneo, Cuneo
Azienda Ospedaliera San Gerardo di Monza, Monza
Children's Healthcare of Atlanta at Egleston, Atlanta
Mersin Universitesi Tip Fakultesi, Mersin
Ege Universitesi Hastanesi - Sağlık Uygulama ve Araştırma Merkezi, Bornova
Hôpital Privé Sévigné, Cesson-Sévigné
Hospital Universitario de Salamanca, Salamanca
Hospital Universitario La Fe, Valencia
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola
Azienda USL della Romagna, Ravenna
Fakultní Nemocnice Brno, Brno
Fakultní Nemocnice Olomouc, Olomouc
Fakultní Nemocnice Ostrava, Ostrava-Poruba
Keski-Suomen keskussairaala Jyväskylä, Jyväskylä
Päijät-Häme Central Hospital, Lahti
Fondazione Policlinico Universitario Agostino Gemelli, Roma
Radboud Universitair Medisch Centrum, Nijmegen
Oslo University Hospital - Rikshospitalet, Oslo
Instituto Português de Oncologia do Porto Francisco Gentil, Porto
Karolinska Universitetssjukhuset - Huddinge, Stockholm
The Leeds Teaching Hospitals NHS Trust, Leeds
King's College Hospital NHS Foundation Trust, London
Lead Sponsor
Amgen
INDUSTRY